New hope for Tough-to-Treat blood cancer: experimental drug enters final testing phase
NCT ID NCT07181239
Summary
This study aims to see if a new drug called CM336 works better than current standard treatments for people with multiple myeloma that has returned or stopped responding to previous therapies. It will involve about 280 adults whose cancer has progressed after at least two prior treatment regimens. Researchers will compare how long patients live without their cancer getting worse when taking CM336 alone versus when receiving other approved treatments chosen by their doctor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.